BioAtla, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.4M
- Price
- $3.27
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.83%
- Volume
- 47.2K
About
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Quick stats
Shares outstanding1.7M
Computed float1.4M
Float / shares84.7%
Cash runway (months)-3.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001826892
Websitehttps://www.bioatla.com
AI Summary
AI-generated1/2
minorneutralpartnership
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics amended its license agreement with BioAtla for CT-202, removing BioAtla's future milestone and royalty obligations in exchange for total payments of $6.5 million.
The deal structure includes a $4.5 million upfront payment and a second installment of $2.0 million due by August 1, 2026.
Context expects to initiate the Phase 1 clinical trial for CT-202, a Nectin-4 x CD3 T cell engager, in the third quarter of 2026.